Organ-specific mesenchymal cells naturally reside in the stroma, where they are exposed to some environmental variables affecting their biology and functions. Risk factors such as diabetes or aging influence their adaptive response. In these cases, permanent epigenetic modifications may be introduced in the cells with important consequences on their local homeostatic activity and therapeutic potential. Numerous results suggest that mesenchymal cells, virtually present in every organ, may contribute to tissue regeneration mostly by paracrine mechanisms. Intriguingly, the heart is emerging as a source of different cells, including pericytes, cardiac progenitors, and cardiac fibroblasts. According to phenotypic, functional, and molecular criteria, these should be classified as mesenchymal cells. Not surprisingly, in recent years, the attention on these cells as therapeutic tools has grown exponentially, although only very preliminary data have been obtained in clinical trials to date. In this review, we summarized the state of the art about the phenotypic features, functions, regenerative properties, and clinical applicability of mesenchymal cells, with a particular focus on those of cardiac origin.

The double life of cardiac mesenchymal cells: epimetabolic sensors and therapeutic assets for heart regeneration / Cencioni, Chiara; Atlante, Sandra; Savoia, Matteo; Martelli, Fabio; Farsetti, Antonella; C Capogrossi, Maurizio; M Zeiher, Andreas; Gaetano, Carlo; Spallotta, Francesco. - In: PHARMACOLOGY & THERAPEUTICS. - ISSN 0163-7258. - 171:(2017), pp. 43-55. [10.1016/j.pharmthera.2016.10.005]

The double life of cardiac mesenchymal cells: epimetabolic sensors and therapeutic assets for heart regeneration

Francesco Spallotta
Ultimo
2017

Abstract

Organ-specific mesenchymal cells naturally reside in the stroma, where they are exposed to some environmental variables affecting their biology and functions. Risk factors such as diabetes or aging influence their adaptive response. In these cases, permanent epigenetic modifications may be introduced in the cells with important consequences on their local homeostatic activity and therapeutic potential. Numerous results suggest that mesenchymal cells, virtually present in every organ, may contribute to tissue regeneration mostly by paracrine mechanisms. Intriguingly, the heart is emerging as a source of different cells, including pericytes, cardiac progenitors, and cardiac fibroblasts. According to phenotypic, functional, and molecular criteria, these should be classified as mesenchymal cells. Not surprisingly, in recent years, the attention on these cells as therapeutic tools has grown exponentially, although only very preliminary data have been obtained in clinical trials to date. In this review, we summarized the state of the art about the phenotypic features, functions, regenerative properties, and clinical applicability of mesenchymal cells, with a particular focus on those of cardiac origin.
2017
Cardiac fibroblast; cardiovascular diseases; epigenetics; mesenchymal stem cells; metabolism; regenerative medicine
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
The double life of cardiac mesenchymal cells: epimetabolic sensors and therapeutic assets for heart regeneration / Cencioni, Chiara; Atlante, Sandra; Savoia, Matteo; Martelli, Fabio; Farsetti, Antonella; C Capogrossi, Maurizio; M Zeiher, Andreas; Gaetano, Carlo; Spallotta, Francesco. - In: PHARMACOLOGY & THERAPEUTICS. - ISSN 0163-7258. - 171:(2017), pp. 43-55. [10.1016/j.pharmthera.2016.10.005]
File allegati a questo prodotto
File Dimensione Formato  
Cencioni_Double_2017.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 543.94 kB
Formato Adobe PDF
543.94 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1679228
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 12
social impact